Contact the Editorial Desk

Editorial correspondence

Chai Peptide welcomes correspondence on the research record: a citation quoted inaccurately, a newer DSIP or Semax study that should be added to the references page, or a correction to how a finding is described. This class of message — one that improves the accuracy or currency of the digest — is the most useful thing this desk receives, and each is read carefully.

The most actionable submissions specify the page in question, the exact passage being challenged, and a supporting reference — a DOI or PubMed ID wherever possible — so the proposed change can be verified before it is acted on.

Editorial mailbox: editors@chaipeptide.com

What this desk cannot do

So that no message goes unanswered for the wrong reason: Chai Peptide is a literature digest, not a clinical service or product vendor, so it cannot advise on or recommend human use of DSIP or Semax, suggest a dose or schedule for any individual, evaluate whether a cited animal or lab finding applies to a specific person's situation, or help locate, source, or purchase either compound from any supplier.

DSIP and Semax are not FDA-approved medicines in the United States; Semax is a registered prescription drug only in Russia and Ukraine. Readers seeking medical guidance should consult a licensed clinician in their jurisdiction. Responses to editorial correspondence are not guaranteed and may be delayed; the mailbox is monitored intermittently.